O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+30.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.45B
AUM Growth
+$5.45B
(+9.1%)
Cap. Flow
-$287M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
39.03%
Holding
130
New
20
Increased
22
Reduced
29
Closed
17
Top Buys
| 1 |
ArriVent BioPharma
AVBP
|
$54.1M |
| 2 |
Cytokinetics
CYTK
|
$47.9M |
| 3 |
Geron
GERN
|
$40.9M |
| 4 |
Q32 Bio
QTTB
|
$38.4M |
| 5 |
Esperion Therapeutics
ESPR
|
$36.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vaxcyte
PCVX
$4B
| $72.8M | 1.33% | 1,066,131 -86,960 | -8% | -$5.94M |
|
27
Crinetics Pharmaceuticals
CRNX
$2.92B
| $64.8M | 1.19% | 1,385,000 -282,360 | -17% | -$13.2M |
|
28
Scholar Rock
SRRK
$3.14B
| $63.5M | 1.16% | 3,574,632 -670,368 | -16% | -$11.9M |
|
29
argenx
ARGX
$43.6B
| $59.7M | 1.09% | 151,600 +67,000 | +79% | +$26.4M |
|
30
Icon
ICLR
$13.8B
| $58.5M | 1.07% | 174,100 +41,900 | +32% | +$14.1M |
|
31
Neurocrine Biosciences
NBIX
$13.8B
| $58.4M | 1.07% | 423,100 -96,179 | -19% | -$13.3M |
|
|
VRNA
32
Verona Pharma
VRNA
$9.16B
| $54.7M | 1% | 3,398,067 -379,711 | -10% | -$6.11M |
|
|
THRD
33
DELISTED
Third Harmonic Bio
THRD
| $54.6M | 1% | 5,779,071 | – | – |
|
|
34
ArriVent BioPharma
AVBP
$776M
| $54.1M | 0.99% | +3,027,328 | New | +$54.1M |
|
35
Neuropace
NPCE
$303M
| $52.9M | 0.97% | 4,003,967 | – | – |
|
36
SI-BONE Inc
SIBN
$719M
| $52M | 0.95% | 3,174,521 +881,990 | +38% | +$14.4M |
|
37
Prelude Therapeutics
PRLD
$68.5M
| $51.7M | 0.95% | 10,909,256 | – | – |
|
38
Vertex Pharmaceuticals
VRTX
$100B
| $51.3M | 0.94% | 122,700 -52,500 | -30% | -$21.9M |
|
39
Terns Pharmaceuticals
TERN
$609M
| $50M | 0.92% | 7,619,135 | – | – |
|
|
40
Cytokinetics
CYTK
$4.23B
| $47.9M | 0.88% | +682,700 | New | +$47.9M |
|
41
Apogee Therapeutics
APGE
$2.17B
| $47.8M | 0.87% | 718,901 -559,000 | -44% | -$37.1M |
|
42
Compass Therapeutics
CMPX
$483M
| $44.3M | 0.81% | 22,362,850 | – | – |
|
|
43
Geron
GERN
$893M
| $42.5M | 0.78% | 12,893,611 +12,408,611 | +2,558% | +$40.9M |
|
44
Syndax Pharmaceuticals
SNDX
$1.41B
| $41.6M | 0.76% | 1,749,000 | – | – |
|
|
45
Q32 Bio
QTTB
$20.9M
| $38.4M | 0.7% | +2,252,987 | New | +$38.4M |
|
|
46
Esperion Therapeutics
ESPR
$448M
| $36.7M | 0.67% | +13,708,731 | New | +$36.7M |
|
47
UnitedHealth
UNH
$281B
| $34.6M | 0.63% | 70,000 | – | – |
|
48
Rhythm Pharmaceuticals
RYTM
$6.85B
| $30.5M | 0.56% | 704,842 +168,200 | +31% | +$7.29M |
|
49
ALX Oncology
ALXO
$62.7M
| $30.3M | 0.56% | 2,717,970 -377,030 | -12% | -$4.2M |
|
50
Vera Therapeutics
VERA
$1.38B
| $29.1M | 0.53% | 675,872 -842,243 | -55% | -$36.3M |
|